================================================================================
BIOLOGY PLAN-EXECUTE DEMO
Multi-Domain Research Coordination with Codex GPT-5.2
Timestamp: 2026-02-19T01:49:40.499861
================================================================================

RESEARCH QUESTION:
The interplay between tumor-intrinsic genomic features and the tumor immune
microenvironment (TIME) has become central to precision immuno-oncology.

Please provide a comprehensive, multi-disciplinary analysis addressing ALL of
the following:

1. How do key tumor-intrinsic genomic features — including tumor mutational
   burden (TMB), microsatellite instability (MSI), specific driver mutations
   (e.g., KRAS, TP53, STK11/LKB1, KEAP1), and chromosomal instability (CIN)
   — vary across major cancer types, and what are the latest large-scale
   genomic studies characterizing these features?

2. At the molecular/protein level, how do these genomic alterations affect
   antigen presentation (MHC-I/II), immune checkpoint ligand expression
   (PD-L1, CTLA-4, LAG-3, TIGIT), and downstream signaling pathways
   (MAPK/ERK, PI3K/AKT/mTOR, JAK-STAT, cGAS-STING)? What are the
   structural and biochemical mechanisms involved?

3. How do these tumor-intrinsic features shape the composition and functional
   state of the tumor immune microenvironment — including CD8+ T cells,
   regulatory T cells, tumor-associated macrophages, myeloid-derived
   suppressor cells, and NK cells? What pathological patterns distinguish
   "hot" vs "cold" tumors?

4. Based on the above biology, what are the most promising biomarker-driven
   immunotherapy combination strategies currently in clinical trials
   (2023–2025), including checkpoint inhibitor combos, bispecifics,
   cancer vaccines, and cellular therapies? What recent clinical trial
   results have been most significant?


================================================================================
STEP 1: PLANNER — Decomposing into domain-specific sub-questions
================================================================================

Planner generated 4 sub-questions:

  1. Domain:  genomics-expert
     Question: Map how TMB, MSI, key driver mutations (KRAS, TP53, STK11/LKB1, KEAP1), and chromosomal instability vary across major cancer types, and identify the most recent large-scale genomic studies (2019–2025) that quantify these features by tumor type and subtype.
     Terms:    tumor mutational burden pan-cancer, MSI prevalence by cancer type, KRAS TP53 STK11 KEAP1 mutation frequency TCGA, chromosomal instability CIN pan-cancer, large-scale sequencing study 2023 2024 2025, COSMIC mutation landscape, cBioPortal pan-cancer TMB MSI

  2. Domain:  protein-biochemistry-expert
     Question: Define the molecular and structural mechanisms by which TMB/MSI, KRAS/TP53/STK11/KEAP1 alterations, and CIN influence antigen presentation (MHC-I/II), immune checkpoint ligand expression (PD-L1, CTLA-4, LAG-3, TIGIT), and signaling (MAPK/ERK, PI3K/AKT/mTOR, JAK-STAT, cGAS-STING).
     Terms:    KRAS PD-L1 regulation mechanism, STK11 LKB1 immune evasion MHC-I, TP53 antigen presentation MHC-I, KEAP1 NRF2 immune checkpoint expression, cGAS-STING chromosomal instability, MAPK ERK PD-L1 transcription, structural biology PD-L1 regulation

  3. Domain:  cancer-biology-expert
     Question: Characterize how tumor-intrinsic genomic features (TMB/MSI, KRAS/TP53/STK11/KEAP1, CIN) shape TIME composition and function, focusing on CD8+ T cells, Tregs, TAMs, MDSCs, and NK cells, and define pathological hallmarks that distinguish hot vs cold tumors.
     Terms:    STK11 cold tumor immune microenvironment, KEAP1 NRF2 immunosuppression macrophages, KRAS immune microenvironment CD8, TP53 immune infiltration, MSI high hot tumors pathology, TMB immune infiltration correlations, CIN immune evasion NK cell

  4. Domain:  clinical-therapeutics-expert
     Question: Identify the most promising biomarker-driven immunotherapy combinations in clinical trials (2023–2025) tied to TMB/MSI, KRAS/TP53/STK11/KEAP1, and CIN, including checkpoint inhibitor combos, bispecifics, vaccines, and cell therapies, and summarize the most significant recent trial results.
     Terms:    TMB high checkpoint inhibitor combination trial 2023 2024 2025, MSI-high combination immunotherapy trial results, KRAS STK11 KEAP1 immunotherapy trial, PD-1 CTLA-4 LAG-3 TIGIT combination trial, bispecific immunotherapy solid tumors 2024, cancer vaccine neoantigen trial results, cell therapy TIL CAR T solid tumors 2023 2025

================================================================================
STEP 2: DOMAIN EXPERTS — Parallel research execution
================================================================================

Launching 4 domain experts in parallel...


All 4 domain experts completed.

================================================================================
STEP 3: SYNTHESIZER — Integrating all findings into final report
================================================================================

Synthesizer is integrating all expert findings...

Synthesis completed in 61.1s


================================================================================
DOMAIN EXPERT REPORTS
================================================================================

──────────────────────────────────────────────────────────────────────
DOMAIN: cancer-biology-expert
──────────────────────────────────────────────────────────────────────
Using `web-search` skill to pull recent, citable literature for an up‑to‑date, mechanistic answer.

**Pathology Hallmarks: Hot vs Cold**
Immune‑inflamed (“hot”) tumors show CD8+ T cells infiltrating tumor nests, often with IFN‑γ/chemokine activity, antigen‑presentation signals, and DC–T cell contact; immune‑excluded tumors have T cells trapped at the invasive margin/stroma with immunosuppressive myeloid/CAF barriers; immune‑desert tumors lack meaningful T‑cell priming or infiltration. These patterns are linked to distinct suppressive elements (MDSCs, Tregs, M2‑like TAMs) in excluded/desert states. ([embopress.org](https://www.embopress.org/doi/10.1038/s44318-025-00650-7))

**Key Findings With Specific Data Points**
- MSI‑high CRC has markedly higher epithelial CD8+ T‑cell densities vs MSI‑low/MSS: ORs for CD3+CD8+ naïve, memory, and regulatory subsets are 3.49, 2.82, and 3.04, respectively; stromal CD3+CD4+ memory T cells are lower (OR 0.68). (Thomas et al., Front Immunol, 2024) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39763680/))  
- STK11/LKB1‑mutant LUAD shows lower CD3+ and CD8+ T‑cell densities (P=0.0019 and P=0.0072), and STK11 alterations are enriched in PD‑L1‑negative tumors even with intermediate/high TMB (P<0.001). (Skoulidis et al., Cancer Discovery, 2018) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6030433/))  
- CIN‑high tumors show immunosuppressive remodeling: ENPP1 overexpression reduces CD8 and NK infiltration and decreases CD8/Treg ratio; chronic STING rewiring drives exhausted CD8 T cells and M2‑like macrophages with granulocytic MDSCs. (Requesens et al., Front Immunol, 2024) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  

**Genomic Features → TIME Mechanisms (CD8, Tregs, TAMs, MDSCs, NK)**
**TMB/MSI/MMRd**
High TMB/MMRd increases neoantigen load and cytosolic DNA sensing (cGAS‑STING), boosting CXCL10/CCL5 and IFN‑β to recruit and activate CD8 and NK cells and improve DC–T cell cross‑talk. This underpins immune‑inflamed phenotypes in MSI‑high tumors. (Requesens et al., Front Immunol, 2024) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  
Spatial transcriptomics shows MMRd CRC enriched for intratumoral immune hubs with activated T cells and chemokine‑expressing malignant/myeloid cells. (Pelka et al., Cell, 2021) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34450029/?utm_source=openai))  
Important nuance: MSI‑high can still develop suppressive feedback (IDO1/CD38, neutrophils) despite being “hot,” indicating that hyper‑inflammation can coexist with immune brakes. (Requesens et al., Front Immunol, 2024) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  

**STK11/LKB1 Loss**
STK11 loss creates a non‑T‑cell‑inflamed, “cold” microenvironment with reduced CD8 infiltration and PD‑L1 expression even at intermediate/high TMB, indicating tumor‑intrinsic immune evasion. (Skoulidis et al., Cancer Discovery, 2018) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6030433/))  
Mechanistically, LKB1 loss promotes neutrophil recruitment and suppressive cytokine programs that blunt T‑cell activity. (Koyama et al., 2016) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26833127/?utm_source=openai))  

**KEAP1/NRF2**
KEAP1‑mutant LUAD suppresses CD103+ DC and CD8+ T‑cell responses; scRNA‑seq shows diminished DC/T‑cell activity, and NRF2 hyperactivation is causative. (Zavitsanou et al., Cell Reports, 2023) ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2211124723013074))  
NRF2 activation in macrophages can skew toward M2‑like programs (CD163/Arg1↑), linking KEAP1/NRF2 to TAM polarization and immunosuppression. (Wang et al., Cell Commun Signal, 2018) ([biosignaling.biomedcentral.com](https://biosignaling.biomedcentral.com/articles/10.1186/s12964-018-0262-x?utm_source=openai))  

**KRAS**
KRAS signaling can downregulate MHC‑I, increase IL‑10/TGF‑β, and recruit MDSCs, promoting Treg induction and TAM/MDSC‑dominant TIME. (Cancers review; lung TME crosstalk review) ([mdpi.com](https://www.mdpi.com/2072-6694/13/3/384?utm_source=openai))  
This supports immune‑excluded or “myeloid‑inflamed” phenotypes with weak cytotoxic CD8 function.

**TP53 and KRAS/TP53**
Across TCGA cancers, TP53 mutations correlate with higher leukocyte levels, suggesting a shift toward inflamed TIME in many contexts. (Thorsson et al., Immunity, 2018) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/))  
In KRAS‑mutant LUAD, TP53 co‑mutation is often linked to higher PD‑L1 and CD8 infiltration signatures and IFN‑γ pathway activity, indicating a more “hot” phenotype in that context. (Recent KRAS immune‑regulation review) ([jeccr.biomedcentral.com](https://jeccr.biomedcentral.com/articles/10.1186/s13046-025-03444-1?utm_source=openai))  
But TP53 effects are context‑dependent; in KRAS/TP53 PDAC models, co‑mutation can expand suppressive myeloid cells and dampen CD8 responses. (KRAS TIME review) ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0753332223018565?utm_source=openai))  

**CIN/Aneuploidy**
High aneuploidy correlates with reduced cytotoxic immune markers (notably CD8) and immune evasion in pan‑cancer analyses. (Davoli et al., Science, 2017) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28104840/?utm_source=openai))  
CIN reprograms the TIME via IFN pathway loss, ENPP1‑adenosine accumulation, M2/Treg/MDSC enrichment, and NK/CD8 suppression; chronic STING activation can paradoxically drive exhaustion. (Requesens et al., Front Immunol, 2024) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  

**Single‑Cell and Spatial Evidence (Recent)**
- MSI/MMRd CRC immune hubs and spatial programs: Pelka et al., Cell, 2021. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34450029/?utm_source=openai))  
- KEAP1‑mutant LUAD scRNA‑seq showing suppressed DC/CD8 responses: Zavitsanou et al., Cell Reports, 2023. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2211124723013074))  
- Large CRC single‑cell atlas (371k cells) for TIME heterogeneity: Li et al., Cancer Immunol Immunother, 2025. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514102/))  

**Important Databases/Resources Consulted**
- TCGA (pan‑cancer immune landscape and driver‑mutation associations). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/))  
- GEO (scRNA‑seq datasets used in recent CRC atlas and KEAP1‑mutant LUAD scRNA‑seq deposition). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514102/))  

**Conflicting Evidence / Open Questions**
- TMB/MMRd can be strongly inflamed yet still fail to sustain effective killing due to compensatory suppressive circuits (IDO1/CD38, neutrophils, Tregs). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  
- CIN shows a dual effect: acute CIN can be immunogenic, while chronic CIN promotes immune exclusion and exhaustion; which balance dominates likely depends on tumor lineage and timing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/))  
- TP53’s immune impact is context‑specific: inflamed in some LUAD settings but myeloid‑suppressive in PDAC models. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0753332223018565?utm_source=openai))  

**Summary**
Across tumors, MSI/MMRd and higher TMB generally drive immune‑inflamed TIME via neoantigens and cGAS‑STING signaling, enriching CD8 and NK cells, yet can still harbor suppressive feedback. STK11 and KEAP1 mutations are strong tumor‑intrinsic “cold” drivers, reducing DC and CD8 infiltration and favoring myeloid‑dominant, PD‑L1‑low milieus. KRAS signaling promotes immunosuppression via MHC‑I loss and Treg/MDSC recruitment, while TP53 co‑mutation can shift KRAS tumors toward inflamed phenotypes in LUAD but not uniformly across cancers. CIN/aneuploidy frequently dampens cytotoxic immunity through IFN‑pathway loss, ENPP1‑adenosine signaling, M2/Treg/MDSC accumulation, and NK/CD8 dysfunction, defining a mechanistic basis for immune‑excluded “cold” tumors.

**Sources**
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC6030433/`
- `https://www.sciencedirect.com/science/article/pii/S2211124723013074`
- `https://pubmed.ncbi.nlm.nih.gov/39763680/`
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC11562473/`
- `https://pubmed.ncbi.nlm.nih.gov/28104840/`
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/`
- `https://link.springer.com/article/10.1038/s44318-025-00650-7`
- `https://pubmed.ncbi.nlm.nih.gov/34450029/`
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC12514102/`
- `https://www.sciencedirect.com/science/article/pii/S0753332223018565`
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC9457687/`

──────────────────────────────────────────────────────────────────────
DOMAIN: clinical-therapeutics-expert
──────────────────────────────────────────────────────────────────────
Using the `web-search` skill to pull 2023–2025 trial results, approvals, and biomarker‑stratified outcomes with citations.

**Key Findings by Biomarker (2023–2025)**

**TMB‑High (tTMB or bTMB)**
- CheckMate 848 (NCT03668119, phase 2; Schenker et al., J Immunother Cancer 2024): in tTMB‑H tumors, nivolumab+ipilimumab ORR 38.6% vs 29.8% with nivolumab; in bTMB‑H tumors, ORR 22.5% vs 15.6%. This is the best contemporary dataset explicitly stratified by TMB for dual‑checkpoint therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39107131/?utm_source=openai))

**MSI‑H/dMMR**
- CheckMate 8HW (NCT04008030, phase 3; André et al., Lancet 2025): nivolumab+ipilimumab improved PFS vs nivolumab alone (HR 0.62, p=0.0003), with median PFS not reached vs 39.3 months at 47‑month median follow‑up; toxicity was higher but manageable. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39874977/?utm_source=openai))
- CheckMate 8HW first‑line vs chemotherapy (interim): nivolumab+ipilimumab produced a 12‑month PFS rate ~79% vs ~21% for chemotherapy; median PFS NR vs 5.9 months; HR ~0.21. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK615899/?utm_source=openai))
- FDA approval (U.S., May 2025): nivolumab+ipilimumab approved for MSI‑H/dMMR metastatic CRC based on CheckMate 8HW; 3‑year PFS ~68% vs ~51% for nivolumab alone. ([cancer.gov](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer?utm_source=openai))
- CheckMate 142 (NCT02060188, phase 2; MSI‑H/dMMR CRC): nivolumab+relatlimab (LAG‑3) ORR 50%, median PFS 27.5 months, OS not reached; 3‑year OS ~56%. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38821718/?utm_source=openai))

**KRAS / STK11 / KEAP1 / TP53**
- KRYSTAL‑7 (NCT04613596, phase 2; KRAS G12C NSCLC): adagrasib+pembrolizumab reported ORR 44% overall and DCR 81% with activity across PD‑L1 subgroups (ORR ~36% in PD‑L1 <1%, 41% in 1–49%, 61% in ≥50%). ([cancernetwork.com](https://www.cancernetwork.com/view/adagrasib-pembrolizumab-yields-improved-survival-in-kras-g12c-mutated-nsclc?utm_source=openai))
- KRYSTAL‑7 PD‑L1 ≥50% subgroup: updated conference report described ORR 59.3% and median PFS 27.7 months with adagrasib+pembrolizumab. ([ajmc.com](https://www.ajmc.com/view/updated-krystal-7-data-show-pfs-beyond-27-months-for-adagrasib-plus-pembro-in-first-line-treatment-of-kras-mutated-nsclc?utm_source=openai))
- POSEIDON biomarker analysis (durvalumab+tremelimumab+chemo; Nature 2024): in STK11/KEAP1‑mutant NSCLC, ORR 42.9% (triplet) vs 30.2% (durvalumab+chemo) vs 28% (chemo). Triplet improved PFS and OS vs chemo (PFS HR 0.52; OS HR 0.50). Median OS in STK11/KEAP1 subgroup 15.8 months vs 7.3 months for durvalumab+chemo, supporting CTLA‑4 add‑on specifically for this resistant genotype. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560846/?utm_source=openai))
- POSEIDON 5‑year OS update (phase 3): triplet showed durable OS benefit vs chemo (HR 0.76); benefit persisted in KRAS‑mutant, STK11‑mutant, and KEAP1‑mutant subgroups. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39243945/?utm_source=openai))
- TP53: public 2023–2025 prospective reports rarely present TP53‑stratified efficacy in immunotherapy combination trials; this remains a gap rather than an established signal (see “Open Questions” below).

**CIN (Chromosomal Instability/Aneuploidy)**
- High aneuploidy/CIN is emerging as a negative predictive marker for ICI response; translational data suggest combining ICI with radiation may partially overcome resistance, but prospective CIN‑stratified trial results are not yet mature. ([uchicagomedicine.org](https://www.uchicagomedicine.org/forefront/immunotherapy-articles/2025/july/chromosomal-abnormality-scores?utm_source=openai))

**Vaccines and Cellular Therapies (Neoantigen/TMB‑linked approaches)**
- KEYNOTE‑942 / mRNA‑4157 (V940) + pembrolizumab (NCT03897881, phase 2b; Lancet 2024): adjuvant melanoma RFS HR 0.561 (p=0.053), 18‑month RFS 79% vs 62%; grade ≥3 TRAEs 25% vs 18%. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38246194/?utm_source=openai))
- FDA Breakthrough Therapy Designation (Feb 22, 2023): mRNA‑4157/V940 + pembrolizumab granted BTD for high‑risk resected melanoma based on KEYNOTE‑942 data. ([investors.modernatx.com](https://investors.modernatx.com/news/news-details/2023/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-With-KEYTRUDAR-pembrolizumab-was-Granted-Breakthrough-Therapy-Designation-by-the-FDA-for-Adjuvant-Treatment-of-Patients-With-High-Risk-Melanom/default.aspx?utm_source=openai))
- TILs + pembrolizumab in metastatic GI cancers (NIH/Nature Medicine 2025): selected TILs + pembrolizumab achieved ORR 23.5% vs 7.7% with selected TILs alone; responses seen in colon, rectum, pancreas, bile duct tumors. ([nih.gov](https://www.nih.gov/news-events/news-releases/combination-immunotherapy-shrank-variety-metastatic-gastrointestinal-cancers))
- Lifileucel (Amtagvi) TIL therapy: FDA accelerated approval Feb 16, 2024 for PD‑1‑refractory melanoma; ORR 31.5% with DoR not reached. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma?utm_source=openai))

**Checkpoint Combinations Beyond PD‑1/CTLA‑4**
- LAG‑3: nivolumab+relatlimab in MSI‑H CRC (CheckMate 142) shows durable activity (see MSI‑H section). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38821718/?utm_source=openai))
- TIGIT (tiragolumab) has disappointed in 2024–2025 phase 3 NSCLC trials, failing to show OS/PFS benefit over PD‑L1 therapy alone (SKYSCRAPER‑01; SKYSCRAPER‑03). This dampens near‑term TIGIT promise and underscores need for better biomarker selection. ([onclive.com](https://www.onclive.com/view/tiragolumab-plus-atezolizumab-fails-to-meet-os-end-point-in-pd-l1-high-nsclc?utm_source=openai))

**FDA Approvals and Breakthrough Therapy Designations (2023–2025)**
- May 2025: FDA approval of nivolumab+ipilimumab for MSI‑H/dMMR metastatic CRC based on CheckMate 8HW. ([cancer.gov](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer?utm_source=openai))
- Feb 2024: FDA accelerated approval of lifileucel (Amtagvi) for PD‑1‑refractory melanoma. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma?utm_source=openai))
- Feb 2023: FDA Breakthrough Therapy Designation for mRNA‑4157/V940 + pembrolizumab in resected high‑risk melanoma. ([investors.modernatx.com](https://investors.modernatx.com/news/news-details/2023/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-With-KEYTRUDAR-pembrolizumab-was-Granted-Breakthrough-Therapy-Designation-by-the-FDA-for-Adjuvant-Treatment-of-Patients-With-High-Risk-Melanom/default.aspx?utm_source=openai))

**Conflicting Evidence / Open Questions**
- TIGIT: multiple phase 3 failures in NSCLC (SKYSCRAPER‑01/03) suggest the biomarker strategy for TIGIT is unresolved. ([onclive.com](https://www.onclive.com/view/tiragolumab-plus-atezolizumab-fails-to-meet-os-end-point-in-pd-l1-high-nsclc?utm_source=openai))
- STK11/KEAP1: strong signal that CTLA‑4 add‑on helps (Nature 2024), but no prospective biomarker‑selected phase 3 regimen is yet standard; optimal sequencing and toxicity tradeoffs remain open. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560846/?utm_source=openai))
- TMB: CheckMate 848 supports dual ICI benefit, but harmonizing tTMB vs bTMB thresholds and tumor‑type heterogeneity remains a key question for clinical implementation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39107131/?utm_source=openai))
- CIN: evidence points to resistance and potential ICI+RT synergy, but CIN‑stratified clinical trial outcomes are still lacking. ([uchicagomedicine.org](https://www.uchicagomedicine.org/forefront/immunotherapy-articles/2025/july/chromosomal-abnormality-scores?utm_source=openai))
- TP53: limited prospective reporting of TP53‑stratified outcomes in recent combo trials makes it difficult to nominate a “promising” TP53‑specific combination in 2023–2025.

**Important Databases/Resources Consulted**
- PubMed (primary trial publications: CheckMate 8HW, CheckMate 848, CheckMate 142, KEYNOTE‑942, POSEIDON 5‑year OS). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39874977/?utm_source=openai))
- ClinicalTrials.gov (trial registry entries, e.g., KRYSTAL‑7 NCT04613596, CodeBreaK 101 NCT04185883). ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04613596?utm_source=openai))
- FDA Oncology approvals (lifileucel). ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma?utm_source=openai))
- NCI / NIH (FDA approval coverage and TIL + pembrolizumab trial results). ([cancer.gov](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer?utm_source=openai))
- Nature / PMC (STK11/KEAP1 biomarker‑driven CTLA‑4 benefit). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560846/?utm_source=openai))

**Most Significant Findings (Bottom Line)**
- MSI‑H/dMMR mCRC now has definitive phase 3 evidence and FDA approval for dual ICI (nivo+ipi), with major PFS advantages and durable disease control. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39874977/?utm_source=openai))
- TMB‑high tumors show clinically meaningful responses to dual ICI in a prospective, biomarker‑defined trial (CheckMate 848). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39107131/?utm_source=openai))
- STK11/KEAP1‑mutant NSCLC appears to be a *true biomarker‑defined subgroup* benefiting from adding CTLA‑4 to PD‑L1+chemo (POSEIDON‑linked Nature 2024 analysis). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560846/?utm_source=openai))
- KRAS G12C NSCLC has an emerging chemo‑sparing targeted+ICI strategy (adagrasib+pembrolizumab), with encouraging ORR and PFS signals but still lacking phase 3 confirmation. ([cancernetwork.com](https://www.cancernetwork.com/view/adagrasib-pembrolizumab-yields-improved-survival-in-kras-g12c-mutated-nsclc?utm_source=openai))
- Neoantigen‑driven vaccines (mRNA‑4157/V940) and TIL‑based cellular therapies are demonstrating clinically meaningful signals when combined with PD‑1 blockade and now have FDA BTD/approval milestones. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38246194/?utm_source=openai))

If you want, I can build a compact table (trial, biomarker, regimen, endpoints, effect sizes) for slide‑ready use, or drill into one biomarker class with full abstract‑level details.

──────────────────────────────────────────────────────────────────────
DOMAIN: protein-biochemistry-expert
──────────────────────────────────────────────────────────────────────
I’ll use the **web-search** skill and rely only on primary sources (research papers and PDB entries), as required.

**Framing (Checkpoint “Ligands” vs Receptors)**  
PD‑L1 is a ligand; CTLA‑4, LAG‑3, and TIGIT are receptors. I interpret your request as mechanisms that control expression of these checkpoint molecules (ligands or receptors) and how antigen presentation and signaling shifts alter their engagement. Where I infer indirect effects (e.g., antigen presentation shaping receptor expression on T cells), I label it explicitly as inference.

**Structural Context: Checkpoint Interfaces (PDB IDs)**  
These structures anchor the biochemical interaction surfaces that are affected by changes in expression.  
- PD‑1/PD‑L1: `4ZQK` (X‑ray, 2.45 Å) defines the PD‑1–PD‑L1 interface and receptor plasticity. ([rcsb.org](https://www.rcsb.org/structure/4zqk?utm_source=openai))  
- CTLA‑4/B7‑1: `1I8L` (X‑ray, 3.0 Å) shows CTLA‑4 homodimerization and bivalent B7‑1 binding. ([rcsb.org](https://www.rcsb.org/structure/1I8L?utm_source=openai))  
- TIGIT/CD155: `3UDW` (X‑ray) shows TIGIT–PVR (CD155) lock‑and‑key interface and cis/trans clustering. ([rcsb.org](https://www.rcsb.org/structure/3UDW?utm_source=openai))  
- LAG‑3/HLA‑DR1: `9BF9` (X‑ray, 3.40 Å; 2024) shows LAG‑3 dimer engaging two MHC‑II molecules. ([rcsb.org](https://www.rcsb.org/structure/9bf9?utm_source=openai))  
- TIM‑3 IgV domain: `6DHB` (X‑ray) provides the TIM‑3 IgV fold; earlier structural work indicates a galectin‑9‑independent binding surface. ([rcsb.org](https://www.rcsb.org/structure/6DHB?utm_source=openai))  

**Core Antigen Presentation Regulators (MHC‑I and MHC‑II)**  
- **MHC‑I transcriptional control**: NLRC5 is a class‑I transactivator; loss reduces MHC‑I expression. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22490867/?utm_source=openai))  
- **IFNγ–JAK–IRF1 axis**: JAK2 loss blocks IFNγ‑induced IRF1 and HLA‑ABC upregulation in NSCLC. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5617399/?utm_source=openai))  
- **MHC‑II control**: IFNγ‑induced MHC‑II depends on KEAP1/CUL3 and chromatin regulators (EMBO reports). ([embopress.org](https://www.embopress.org/doi/abs/10.15252/embr.201745553?utm_source=openai))  

---

## Mechanisms by Alteration

### 1. TMB/MSI
**Mechanistic impact on antigen presentation**  
- **MSI generates frameshift neoantigens**: MSI produces frameshift peptides (FSPs) that can elicit tumor‑specific CD8 responses. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27467916/?utm_source=openai))  
- **Antigen presentation escape in MSI**: B2M (β2‑microglobulin) is frequently mutated in MSI‑H tumors, disrupting MHC‑I surface expression. Data point: MSI‑H CRC shows B2M mutation in 57.5% (23/40), with lower rates in MSI‑H GC (23.9%) and EC (13.6%). ([academic.oup.com](https://academic.oup.com/oncolo/article/28/3/e136/7022155?utm_source=openai))  
- **IFN pathway escape in MSI**: MSI‑derived JAK1 frameshift mutations impair IFNγ‑induced MHC‑I pathway genes (e.g., LMP7, HLA class I). ([oncotarget.com](https://www.oncotarget.com/article/9414/text/?utm_source=openai))  

**Checkpoint expression**  
- **Inference**: High neoantigen load (from TMB/MSI) can drive chronic IFN signaling and T cell activation, indirectly increasing checkpoint receptor expression (CTLA‑4, LAG‑3, TIGIT) on T cells. This inference is grounded in the mechanistic link between antigen presentation and T‑cell activation, not a direct tumor‑cell transcriptional mechanism.  
- **Direct tumor effect**: MSI‑linked JAK1/2 defects reduce IFNγ response, lowering IFN‑inducible PD‑L1 and MHC‑I. ([oncotarget.com](https://www.oncotarget.com/article/9414/text/?utm_source=openai))  

### 2. CIN → cGAS–STING
**Mechanistic impact on signaling**  
- **Micronuclei sensing**: Genome instability creates micronuclei; their rupture recruits cGAS, activating STING and innate signaling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28738408/?utm_source=openai))  
- **CIN‑driven pro‑metastatic signaling**: In CIN cells, cGAS–STING activates non‑canonical NF‑κB and promotes invasion/metastasis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29342134/?utm_source=openai))  
- **CIN‑dependent survival signaling**: cGAS–STING can drive IL‑6/STAT3 survival programs in CIN cancers (Nature 2022). ([nature.com](https://www.nature.com/articles/s41586-022-04847-2))  

**Impact on checkpoint ligands and antigen presentation**  
- **NF‑κB/STAT3 link to PD‑L1**: NF‑κB and STAT3 are transcriptional regulators of PD‑L1 (mechanistically supported by autophagy/NF‑κB PD‑L1 induction and MAPK‑STAT3 PD‑L1 regulation in tumors). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30925913/?utm_source=openai))  
- **Inference**: CIN‑driven chronic cGAS–STING signaling can elevate PD‑L1 via NF‑κB/STAT3, but context may skew toward immunosuppression or inflammation.  

### 3. KRAS (G12C/D/V)
**Structural and biochemical mechanism**  
- Ras–RasGAP structure (`1WQ1`) shows GAP “arginine finger” and G12/Q61 geometry; G12 substitutions sterically disrupt GTPase activation, favoring GTP‑bound active KRAS. This applies to G12C/D/V. ([rcsb.org](https://www.rcsb.org/structure/1wq1?utm_source=openai))  

**Downstream signaling and immune effects**  
- **MAPK/ERK → PD‑L1 transcription**: KRAS‑mutant lung cancers require MAPK for PD‑L1 expression; AP‑1 (c‑JUN) binds PD‑L1 enhancer, STAT3 partially contributes. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5112979/?utm_source=openai))  
- **RAS → PD‑L1 mRNA stabilization**: Oncogenic RAS stabilizes PD‑L1 mRNA via AU‑rich elements; MEK/ERK inhibition reduces PD‑L1. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29246442/?utm_source=openai))  
- **RAS → PI3K contribution**: MEK and PI3K both contribute to PD‑L1 protein levels (PI3K affects translation). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5746170/?utm_source=openai))  
- **Antigen presentation suppression**: KRAS G12V signaling decreases TAP1, TAPBP, HLA‑A/B/C and B2M expression. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5746170/?utm_source=openai))  
- **ERK–autophagy axis**: In KRAS‑mutant iCCA, ERK inhibition lowers PD‑L1 by activating autophagy; tissue correlation p‑ERK vs PD‑L1 in 92 samples: Spearman r = 0.56, P < 0.0001. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35305624/?utm_source=openai))  

### 4. TP53 Hotspots (e.g., R175H, R248Q, R273H)
**Structural mechanism**  
- p53 core domain structure (`1TSR`) defines the DNA‑binding loops where hotspot mutations occur; these mutations disrupt sequence‑specific DNA binding. ([rcsb.org](https://www.rcsb.org/structure/1tsr?utm_source=openai))  

**Antigen presentation and PD‑L1**  
- **MHC‑I**: p53 directly upregulates ERAP1, increasing MHC‑I surface expression. Loss of p53 reduces ERAP1 and MHC‑I. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23965983/?utm_source=openai))  
- **PD‑L1 via miR‑34**: p53 induces miR‑34; miR‑34 suppresses PD‑L1. p53 loss or mutation reduces miR‑34 and increases PD‑L1. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26577528/?utm_source=openai))  

### 5. STK11 (LKB1) Loss
**STING suppression and immune evasion**  
- LKB1 loss in KRAS‑driven lung cancer is associated with transcriptional suppression of STING; in patient samples, LKB1 loss correlates with reduced STING protein (P < 0.0001). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6328329/?utm_source=openai))  
- Mechanism involves DNMT1/EZH2‑linked silencing, dampening type‑I IFN programs and lowering immune recruitment/PD‑L1. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6328329/?utm_source=openai))  

### 6. KEAP1/NRF2 Alterations
**PD‑L1 protein stability**  
- KEAP1 can ubiquitinate PD‑L1 (K48‑linked) and promote PD‑L1 degradation; KEAP1 loss stabilizes PD‑L1 protein. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10899596/?utm_source=openai))  

**Antigen presentation and STING**  
- NRF2‑activated tumors show reduced expression of MHC‑I antigen‑presentation genes (immunoediting signature). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37839356/?utm_source=openai))  
- NRF2 can suppress STING pathway activity in KRAS/KEAP1‑co‑mutant NSCLC. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37492744/?utm_source=openai))  
- KEAP1 and CUL3 are required for IFNγ‑induced MHC‑II expression in a genetic/chemical screen. ([embopress.org](https://www.embopress.org/doi/abs/10.15252/embr.201745553?utm_source=openai))  

---

## Signaling Integration Map (Mechanistic Links)
- **MAPK/ERK**: KRAS activation → AP‑1/ERK → PD‑L1 transcription; ERK also stabilizes PD‑L1 via autophagy suppression. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5112979/?utm_source=openai))  
- **PI3K/AKT/mTOR**: RAS–PI3K contributes to PD‑L1 protein expression (translation). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5746170/?utm_source=openai))  
- **JAK‑STAT**: IFNγ → JAK2 → IRF1 → HLA‑ABC; JAK2 loss blocks this. MSI‑linked JAK1 frameshifts also impair MHC‑I induction. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5617399/?utm_source=openai))  
- **cGAS‑STING**: CIN → micronuclei rupture → cGAS/STING → NF‑κB, type‑I IFN, IL‑6/STAT3 programs; LKB1 and NRF2 can suppress this axis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28738408/?utm_source=openai))  

---

## Conflicting Evidence / Open Questions
- **KEAP1/NRF2 and PD‑L1**: KEAP1 promotes PD‑L1 degradation (suggesting KEAP1 loss increases PD‑L1), yet NRF2‑activated tumors show reduced MHC‑I gene expression and broader immunoediting; the net checkpoint phenotype likely depends on tissue and cytokine context. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10899596/?utm_source=openai))  
- **cGAS‑STING in CIN**: Acute activation can enhance immune surveillance (type‑I IFN), but chronic CIN can drive NF‑κB/IL‑6/STAT3 pro‑survival and metastasis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28738408/?utm_source=openai))  
- **TIM‑3 ligands**: Structural evidence suggests a galectin‑9‑independent binding surface, leaving physiological ligand usage context‑dependent. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1074761307001781?utm_source=openai))  

---

## Most Significant Findings (Summary)
1. **KRAS G12C/D/V** lock KRAS in active signaling states via impaired GAP‑mediated hydrolysis, driving MAPK/ERK‑ and PI3K‑dependent PD‑L1 upregulation and reducing antigen presentation genes (TAP1, HLA‑A/B/C, B2M). ([rcsb.org](https://www.rcsb.org/structure/1wq1?utm_source=openai))  
2. **TP53 loss/hotspots** reduce MHC‑I via ERAP1 downregulation and elevate PD‑L1 through loss of miR‑34, tying genome integrity to antigen processing and checkpoint control. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23965983/?utm_source=openai))  
3. **STK11/LKB1 loss** epigenetically silences STING, dampening DNA‑sensing and IFN programs that normally support antigen presentation and checkpoint induction. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6328329/?utm_source=openai))  
4. **CIN activates cGAS–STING** via micronuclei, but chronic signaling can switch to NF‑κB/IL‑6/STAT3 programs that support immune evasion and metastasis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28738408/?utm_source=openai))  
5. **MSI generates frameshift neoantigens** but also selects for antigen‑presentation loss (B2M, JAK1), creating a balance of high neoantigen load and immune escape. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27467916/?utm_source=openai))  

---

## Databases / Resources Consulted
- **RCSB PDB** for checkpoint and core signaling protein structures (`4ZQK`, `1I8L`, `3UDW`, `9BF9`, `6DHB`, `1WQ1`, `1TSR`). ([rcsb.org](https://www.rcsb.org/structure/4zqk?utm_source=openai))  
- **Primary literature repositories**: PubMed/PMC for mechanistic and structural biology papers cited above. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23965983/?utm_source=openai))  

---

If you want, I can map these mechanisms onto a signaling diagram (textual or figure-ready) or drill into one pathway (e.g., KRAS→PD‑L1 regulation) with residue‑level details and specific motifs.

──────────────────────────────────────────────────────────────────────
DOMAIN: genomics-expert
──────────────────────────────────────────────────────────────────────
Using `web-search` skill to pull 2019–2025 pan-cancer data with citations.

**Data Sources**
- TCGA PanCancer Atlas and cBioPortal (for TCGA/GENIE access and pan-cancer context). citeturn9view0turn9view1  
- COSMIC v98 (curated somatic mutation knowledgebase; 1.55M samples and 7.4M coding mutations). citeturn14view0  
- AACR Project GENIE 2024 dataset scale (184,988 patients; 214,487 samples). citeturn18search0  

**Recent Large-Scale Studies (2019–2025)**
- Li, Gao, Wang. *Frontiers in Immunology* 2023: TCGA pan-cancer TMB distribution (32 tumor types), including high-TMB percentages by cancer type. citeturn7view0  
- Lin et al. *npj Precision Oncology* 2024: MSI‑H prevalence in 174,166 F1CDx tumors with tumor-type–specific rates (overall MSI‑H 2.4%). citeturn8search1turn9view0  
- Sivakumar et al. *Genetics* 2021: pan-cancer allelic imbalance (AI) burden across 11,074 tumors; AI used as a CIN proxy with high/low tumor-type medians. citeturn16search0  
- Frille et al. *Frontiers in Oncology* 2024: LUAD mutation frequencies in 4,109 cases (TP53 45.6%, KRAS 34.17%, STK11 16.82%, KEAP1 14.35%). citeturn8search0  
- Loong et al. *Translational Lung Cancer Research* 2020: pan-cancer KRAS frequencies in 11,951 Chinese tumors (pancreas 81.5%, CRC 48.9%, biliary 23.5%, lung 11.7%, stomach 10.3%). citeturn11search3turn14view0  
- Wang et al. *Discover Oncology* 2025: LUSC TCGA mutation profile with TP53 at 74.9%. citeturn20search0turn21view0  
- Gheibi et al. *Cancer Genetics* 2025: CRC TP53 prevalence 51% overall and 81% in metastatic CRC. citeturn12view1  

**Cross-Cancer Map**

**TMB**
- Highest high‑TMB proportions in TCGA were SKCM 49.4%, LUAD 36.9%, LUSC 28.1%. citeturn7view0  
- High‑TMB (>10%) cancer types included BLCA, UCEC, COAD, STAD, DLBC, HNSC, ESCA, PAAD, and CESC; very low (<1%) in THYM, PRAD, KIRC, KIRP, LAML, OV, PCPG, THCA. citeturn7view0  
- Pan-cancer high‑TMB rate was 11.5% using ≥10 mutations/Mb. citeturn7view0  

**MSI**
- Overall MSI‑H prevalence was 2.4% across 174,166 tumors. citeturn8search1turn9view0  
- Highest MSI‑H by tumor type: endometrioid endometrial carcinoma 32%, small intestine adenocarcinoma 10%, CRC 7%, gastric 6%, ovarian endometrioid 6%. citeturn8search1turn9view0  
- Several additional sites clustered at ~3–4% (vaginal, cervical, skin adnexal, kidney urothelial). citeturn8search1turn9view0  

**Driver Mutations**
- KRAS: pancreas 81.5%, CRC 48.9%, biliary 23.5%, lung 11.7%, stomach 10.3% (Chinese pan-cancer cohort). citeturn11search3turn14view0  
- TP53: LUAD 45.6% (Frille), LUSC 74.9% (Wang), CRC 51% overall and 81% metastatic (Gheibi). citeturn8search0turn20search0turn12view1  
- STK11/KEAP1: LUAD 16.82% and 14.35% respectively, indicating LUAD‑enriched co‑mutations among major tumor types. citeturn8search0  

**Chromosomal Instability (CIN / AI burden)**
- Pan-cancer median AI burden was 32%; highest medians >60% in TGCT, ESCA, ACC, OV; high >50% in UCS and in both LUAD/LUSC; lowest <10% in THCA, LAML, THYM, PRAD. citeturn16search0  

**Cancer-Type Snapshots (Major Tumors)**
- NSCLC (LUAD): high‑TMB 36.9%; TP53 45.6%, KRAS 34.17%, STK11 16.82%, KEAP1 14.35%; CIN high (AI >50% for LUAD). citeturn7view0turn8search0turn16search0  
- NSCLC (LUSC): high‑TMB 28.1%; TP53 74.9%; CIN high (AI >50% for LUSC). citeturn7view0turn20search0turn16search0  
- CRC: MSI‑H 7%; KRAS 48.9%; TP53 51% overall (81% metastatic CRC). citeturn8search1turn11search3turn12view1  
- Melanoma (SKCM): highest high‑TMB rate at 49.4%; MSI‑H not among tumor types with elevated prevalence in a 174k‑sample survey (inference: MSI‑H is uncommon relative to the listed high‑MSI cancers). citeturn7view0turn8search1  
- Endometrioid endometrial carcinoma: MSI‑H 32%; UCEC is among high‑TMB tumor types and shows substantial high‑TMB even within MSI‑H subsets. citeturn8search1turn7view0  
- Ovarian: OV shows very low high‑TMB (<1%); ovarian endometrioid MSI‑H is 6%; CIN is among the highest (AI >60%). citeturn7view0turn8search1turn16search0  
- Pancreatic: KRAS 81.5%; PAAD is among TCGA tumor types with >10% high‑TMB. citeturn11search3turn7view0  

**Conflicts and Open Questions**
- Cohort effects: TCGA (primary untreated tumors) vs real‑world datasets (F1CDx, GENIE) can shift apparent MSI/TMB and driver frequencies; direct cross-dataset harmonization remains an open need. citeturn7view0turn8search1turn18search0  
- Population effects: KRAS frequencies in the Chinese cohort differ from COSMIC‑weighted or TCGA‑weighted expectations, emphasizing ancestry and sampling differences. citeturn11search3turn14view0  
- CIN metrics: AI burden is one operationalization; other CIN/aneuploidy metrics can yield different rank orders by tumor type. citeturn16search0  

**Summary**
- TMB peaks in melanoma and smoking-associated lung cancers, with several GI and GU tumors showing intermediate high‑TMB subsets. citeturn7view0  
- MSI‑H is concentrated in endometrioid endometrial, small intestine, CRC, and gastric cancers, with low prevalence elsewhere. citeturn8search1turn9view0  
- KRAS is dominant in pancreas and CRC; TP53 is highest in LUSC and substantial in LUAD/CRC; STK11/KEAP1 are LUAD‑enriched. citeturn11search3turn8search0turn20search0turn12view1  
- CIN is highest in TGCT/ESCA/ACC/OV and also high in LUSC/LUAD, while remaining low in thyroid, AML, thymoma, and prostate. citeturn16search0  

If you want, I can assemble these into a concise per‑tumor‑type table (TSV/CSV) for direct use in slides or reports.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
INTEGRATED SYNTHESIS REPORT
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**I. Executive Summary**
- Pan‑cancer data show distinct distributions of TMB, MSI‑H, and CIN by tumor type, with melanoma and smoking‑associated lung cancers enriched for high TMB; endometrioid endometrial, small intestine, colorectal, and gastric cancers enriched for MSI‑H; and CIN highest in TGCT/ESCA/ACC/OV and high in both LUAD/LUSC. These genomic strata set the baseline likelihood of immune‑inflamed versus immune‑excluded phenotypes.
- MSI‑H/dMMR and high‑TMB tumors generate abundant neoantigens and activate cGAS–STING/IFN programs that support antigen presentation and CD8/NK recruitment, yet frequently acquire immune‑escape mutations (e.g., B2M, JAK1) that blunt MHC‑I and IFN signaling.
- Driver mutations shape checkpoint biology at the molecular level: KRAS activates MAPK/ERK and PI3K to raise PD‑L1 and suppress antigen presentation; TP53 loss reduces ERAP1/MHC‑I and lifts PD‑L1 via miR‑34 loss; STK11/LKB1 silences STING and dampens IFN programs; KEAP1/NRF2 alters PD‑L1 stability and antigen‑presentation gene expression.
- Tumor‑intrinsic genotypes map to distinct TIME states: MSI‑H/dMMR is typically “hot”; STK11 and KEAP1 alterations drive “cold” phenotypes with low CD8 infiltration; CIN skews toward myeloid‑dominant, exhausted, or excluded states despite innate sensing.
- Clinical trials 2023–2025 support biomarker‑driven strategies: dual ICI in MSI‑H/dMMR mCRC (CheckMate 8HW) and TMB‑H tumors (CheckMate 848); CTLA‑4 add‑on for STK11/KEAP1‑mutant NSCLC (POSEIDON biomarker analysis); KRAS G12C targeted + PD‑1 strategies in NSCLC (KRYSTAL‑7); and neoantigen vaccines or TIL therapy combined with PD‑1 blockade.
- Major gaps include harmonizing TMB and CIN assays, prospective TP53‑stratified outcomes, and resolving chronic cGAS–STING signaling’s dual immunogenic and immunosuppressive roles.

---

**II. Integrated Analysis (Genome → Protein → TIME → Clinical Outcomes)**

**Genomic landscape across major cancers**
Large-scale pan‑cancer datasets define how immune‑relevant genomic features distribute by tumor type. TMB peaks in SKCM (49.4%), LUAD (36.9%), and LUSC (28.1%), with intermediate‑high rates in BLCA, UCEC, COAD, STAD, DLBC, HNSC, ESCA, PAAD, and CESC; very low rates occur in THYM, PRAD, KIRC, KIRP, LAML, OV, PCPG, and THCA. MSI‑H prevalence is overall 2.4% across 174,166 tumors, with the highest rates in endometrioid endometrial carcinoma (32%), small intestine adenocarcinoma (10%), CRC (7%), and gastric cancer (6%). CIN, quantified by allelic imbalance burden, is highest in TGCT/ESCA/ACC/OV and remains high in LUAD/LUSC. Driver mutation frequencies show tumor‑type enrichment: KRAS is dominant in pancreas (81.5%) and CRC (48.9%); TP53 is high in LUSC (74.9%) and substantial in LUAD (45.6%) and CRC (51% overall; 81% in metastatic CRC); STK11 (16.82%) and KEAP1 (14.35%) are LUAD‑enriched.

These distributions establish the first layer of immune “predisposition.” Tumors with high TMB or MSI‑H are more likely to be immunogenic, whereas CIN‑high cancers often show immune evasion despite innate sensing signals.

**Molecular mechanisms linking genotype to antigen presentation and checkpoint biology**
At the protein level, genomic lesions regulate antigen presentation and checkpoint ligand/receptor engagement through defined signaling axes and biochemical mechanisms.

- **TMB/MSI → antigen load and escape**: MSI creates frameshift peptides that can be highly immunogenic, but MSI‑H tumors frequently acquire antigen‑presentation escape: B2M mutations are common in MSI‑H CRC (57.5%) and less frequent in MSI‑H gastric (23.9%) and endometrial (13.6%) cancers. MSI‑linked JAK1 frameshifts blunt IFNγ‑induced MHC‑I genes, reducing IFN‑inducible PD‑L1 and antigen presentation.
- **KRAS → MAPK/ERK and PI3K effects**: Structural data (RAS–RasGAP, `1WQ1`) show how G12 substitutions lock KRAS in the active GTP‑bound state. In KRAS‑mutant lung cancers, MAPK/ERK signaling drives PD‑L1 transcription through AP‑1; PI3K contributes to PD‑L1 protein expression. KRAS G12V suppresses antigen presentation genes (TAP1, TAPBP, HLA‑A/B/C, B2M), reducing MHC‑I presentation.
- **TP53 loss → MHC‑I down, PD‑L1 up**: p53 directly upregulates ERAP1, increasing MHC‑I presentation. p53 loss or hotspot mutations reduce ERAP1 and thus MHC‑I. p53 also induces miR‑34, which suppresses PD‑L1; loss of p53 increases PD‑L1.
- **STK11/LKB1 loss → STING silencing**: LKB1 loss suppresses STING expression via epigenetic repression (DNMT1/EZH2), limiting type‑I IFN responses and reducing antigen presentation and PD‑L1 induction.
- **KEAP1/NRF2 axis → PD‑L1 stability and immunoediting**: KEAP1 ubiquitinates PD‑L1 for proteasomal degradation; KEAP1 loss stabilizes PD‑L1 protein. NRF2 activation is associated with reduced MHC‑I antigen presentation gene expression and STING suppression in KRAS/KEAP1 co‑mutant NSCLC.
- **CIN → cGAS–STING with dual outputs**: CIN generates micronuclei that activate cGAS–STING, driving type‑I IFN and NF‑κB/IL‑6/STAT3 programs. Acute activation can be immunostimulatory; chronic activation shifts toward pro‑survival, pro‑metastatic signaling and may raise PD‑L1 via NF‑κB/STAT3.

**TIME composition and pathological patterns**
These molecular programs converge on characteristic TIME states.

- **MSI‑H/dMMR and high‑TMB**: High neoantigen load and active cGAS–STING/IFN programs promote immune‑inflamed (“hot”) tumors with CD8+ infiltration and DC–T cell interactions. In MSI‑H CRC, epithelial CD8+ T‑cell densities are substantially higher (ORs 2.82–3.49 across CD8 subsets), consistent with inflamed pathology. Yet MSI‑H tumors can still develop suppressive feedback (e.g., IDO1/CD38, neutrophils), creating inflamed but functionally constrained states.
- **STK11/LKB1 and KEAP1**: STK11 loss yields PD‑L1‑low, non‑T‑cell‑inflamed LUAD with reduced CD3/CD8 densities. KEAP1/NRF2 hyperactivation suppresses CD103+ DCs and CD8 responses, and macrophage polarization toward M2‑like states has been reported with NRF2 activation.
- **KRAS**: KRAS signaling can downregulate MHC‑I and recruit suppressive myeloid populations (MDSCs, M2‑like TAMs), driving immune‑excluded or myeloid‑inflamed phenotypes with weak cytotoxic function.
- **TP53 context dependence**: Pan‑cancer analyses link TP53 mutations to higher leukocyte signals overall, but in specific contexts (e.g., KRAS/TP53 PDAC models) co‑mutation expands suppressive myeloid cells and dampens CD8 responses.
- **CIN/Aneuploidy**: CIN is associated with reduced cytotoxic immune markers and immune evasion in pan‑cancer studies. Mechanistically, ENPP1‑adenosine signaling, M2/Treg/MDSC enrichment, and NK/CD8 suppression contribute to immune exclusion. Chronic STING activation can exhaust CD8 T cells and enrich suppressive myeloid cells.

**Clinical outcomes and biomarker‑aligned trials (2023–2025)**
The clinical data reflect these mechanistic patterns.

- **MSI‑H/dMMR mCRC**: CheckMate 8HW shows PFS improvement with nivolumab+ipilimumab versus nivolumab alone (HR 0.62; median PFS not reached vs 39.3 months at 47‑month follow‑up). FDA approval followed in May 2025. These outcomes align with the inflamed TIME and high neoantigen burden of MSI‑H tumors.
- **TMB‑high tumors**: CheckMate 848 demonstrates higher ORR with nivolumab+ipilimumab vs nivolumab alone in tTMB‑H (38.6% vs 29.8%) and bTMB‑H (22.5% vs 15.6%) cohorts, supporting dual ICI in high‑neoantigen settings.
- **STK11/KEAP1‑mutant NSCLC**: POSEIDON biomarker analysis indicates improved ORR and OS with durvalumab+tremelimumab+chemo in STK11/KEAP1‑mutant tumors (OS HR ~0.50; median OS 15.8 months vs 7.3 months for durvalumab+chemo), consistent with rescuing “cold” TIME via CTLA‑4 add‑on.
- **KRAS G12C NSCLC**: KRYSTAL‑7 shows encouraging ORR (~44% overall) for adagrasib+pembrolizumab, with activity across PD‑L1 subgroups, reflecting the need to counteract KRAS‑driven immunosuppression with combined targeted and immune therapy.
- **Neoantigen vaccines and cellular therapies**: KEYNOTE‑942 (mRNA‑4157/V940 + pembrolizumab) improved RFS (HR 0.561) in adjuvant melanoma. Lifileucel (TIL therapy) gained FDA accelerated approval in 2024 for PD‑1‑refractory melanoma (ORR 31.5%). These approaches leverage neoantigen presentation and T‑cell reinvigoration.

---

**III. Translational Implications**
- **MSI‑H/dMMR and high‑TMB**: Robust antigenicity and T‑cell infiltration predict benefit from dual ICI. However, frequent B2M/JAK1 defects justify integrating antigen‑presentation assays into clinical decision‑making and testing salvage strategies (e.g., NK‑cell‑directed approaches or bispecifics).
- **STK11/KEAP1‑mutant NSCLC**: Mechanistic evidence for STING silencing and DC/T‑cell exclusion aligns with clinical benefit from CTLA‑4 add‑on. This defines a true biomarker‑driven subgroup where “immune‑cold” genotypes can be re‑sensitized.
- **KRAS‑mutant tumors**: MAPK/ERK‑driven PD‑L1 upregulation and antigen‑presentation suppression argue for rational combination of KRAS inhibitors with PD‑1 blockade, potentially with agents that restore MHC‑I (e.g., IFN pathway agonists).
- **CIN‑high tumors**: CIN‑induced chronic STING signaling can yield immunosuppressive myeloid states. Combinations pairing ICI with agents that modulate STING, adenosine pathways (ENPP1/CD73), or myeloid checkpoints are translationally logical but remain under‑tested.
- **TP53‑altered tumors**: Loss of miR‑34‑mediated PD‑L1 suppression and ERAP1‑dependent MHC‑I suggests therapeutic windows for PD‑1 blockade plus agents that restore antigen processing or mimic miR‑34.

---

**IV. Key Challenges and Knowledge Gaps**
- **Assay harmonization**: TMB and CIN thresholds differ across platforms (tTMB vs bTMB; AI burden vs aneuploidy), limiting cross‑trial comparability.
- **Context‑dependent immune phenotypes**: TP53 and CIN have divergent immune effects by tissue context and timing (acute vs chronic cGAS–STING), complicating biomarker‑based stratification.
- **Antigen‑presentation escape**: High‑TMB/MSI tumors commonly acquire B2M/JAK1 defects; clinical pathways to detect and overcome these are not standardized.
- **Checkpoint selection**: TIGIT has failed in phase 3 NSCLC trials, indicating incomplete biomarker strategy or patient selection.
- **Prospective genotype‑stratified trials**: Aside from MSI‑H/dMMR and emerging STK11/KEAP1 data, few trials are prospectively powered for driver‑defined immune outcomes.

---

**V. Future Directions**
1. **Prospective, genotype‑stratified trials**: Power studies for STK11/KEAP1, TP53, and CIN‑high cohorts with defined immune endpoints.
2. **Integrated biomarker panels**: Combine TMB/MSI with antigen‑presentation integrity (B2M/JAK1), IFN signatures, and myeloid markers to refine ICI selection.
3. **Mechanism‑guided combinations**:  
   - KRAS‑mutant: KRAS inhibitor + PD‑1 + antigen‑presentation restoration (e.g., IFN pathway agonists).  
   - CIN‑high: ICI + adenosine‑pathway blockade or STING modulators; integrate radiation where CIN suggests innate sensing.
4. **Spatial and single‑cell TIME mapping**: Expand spatial transcriptomics across tumor types to link genotype to immune‑cell localization and functional states.
5. **Neoantigen‑driven therapies**: Move personalized vaccines and TILs into earlier lines for high‑TMB and MSI‑H disease, with monitoring for antigen‑presentation loss.

---

**VI. References**
```text
Pan‑cancer genomics and prevalence
- Li, Gao, Wang. Front Immunol (2023) — TCGA pan‑cancer TMB distribution.
- Lin et al. npj Precision Oncology (2024) — MSI‑H prevalence in 174,166 tumors.
- Sivakumar et al. Genetics (2021) — pan‑cancer AI burden (CIN proxy).
- Frille et al. Front Oncol (2024) — LUAD mutation frequencies.
- Loong et al. Transl Lung Cancer Res (2020) — pan‑cancer KRAS frequencies.
- Wang et al. Discover Oncology (2025) — LUSC mutation profile.
- Gheibi et al. Cancer Genetics (2025) — CRC TP53 prevalence.

Protein/biochemistry and immune regulation
- PD‑1/PD‑L1 structure: PDB 4ZQK.
- CTLA‑4/B7‑1 structure: PDB 1I8L.
- TIGIT/CD155 structure: PDB 3UDW.
- LAG‑3/HLA‑DR1 structure: PDB 9BF9.
- TIM‑3 IgV: PDB 6DHB.
- KRAS‑RasGAP structure: PDB 1WQ1.
- p53 core domain: PDB 1TSR.
- NLRC5 as MHC‑I transactivator (2012).
- JAK2 loss blocks IFNγ‑induced MHC‑I (NSCLC).
- KEAP1/CUL3 control IFNγ‑induced MHC‑II.
- MSI frameshift neoantigens; B2M mutations in MSI‑H; JAK1 frameshifts impair IFNγ response.
- KRAS‑MAPK/ERK and PI3K regulation of PD‑L1; KRAS G12V suppresses antigen‑presentation genes.
- p53–ERAP1 and p53–miR‑34–PD‑L1 axis.
- LKB1 loss silences STING.
- KEAP1 regulates PD‑L1 stability; NRF2 suppresses MHC‑I and STING.

Tumor immune microenvironment and pathology
- Hot vs cold tumor pathology patterns and immune‑cell distributions.
- MSI‑H CRC CD8+ density ORs (Thomas et al., 2024).
- STK11/LKB1‑mutant LUAD CD3/CD8 depletion and PD‑L1‑low state (Skoulidis et al., 2018).
- CIN and ENPP1‑adenosine, chronic STING rewiring, and immune suppression.
- Pan‑cancer aneuploidy linked to reduced cytotoxic immunity (Davoli et al., 2017).
- Single‑cell/spatial studies in CRC and LUAD.

Clinical trials and approvals (2023–2025)
- CheckMate 8HW (Lancet 2025) — MSI‑H/dMMR mCRC, nivolumab+ipilimumab.
- FDA approval (May 2025) — nivolumab+ipilimumab for MSI‑H/dMMR mCRC.
- CheckMate 848 (JITC 2024) — TMB‑high dual ICI.
- POSEIDON biomarker analysis (Nature 2024) — STK11/KEAP1‑mutant NSCLC benefit.
- KRYSTAL‑7 (NCT04613596) — adagrasib+pembrolizumab in KRAS G12C NSCLC.
- KEYNOTE‑942 (Lancet 2024) — mRNA‑4157/V940 + pembrolizumab.
- Lifileucel FDA accelerated approval (2024).
- TILs + pembrolizumab in metastatic GI cancers (2025).
- SKYSCRAPER‑01/03 — TIGIT failures in NSCLC.
```

================================================================================
EXECUTION SUMMARY
================================================================================
Domain experts:         4
Total research output:  37,915 chars
Synthesis output:       13,703 chars
Total elapsed time:     673.5s
Status:                 All agents completed successfully!